Hilary Clinton has recently sent shockwaves through the Pharma & Biotech sector with her plan to lower prescription drug costs, bringing the issue of drug pricing squarely into public focus. Over September the S&P Pharma index was down some 20%, with the value of BELLUS Health shares suffering broadly in line, down 16% over the last month. This is at a time where the company’s rare disease pipeline is rapidly progressing. Its lead candidate KIACTATM is months away from releasing
12 Oct 2015
Caught in the crossfire....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Caught in the crossfire....
Blue Star Capital Plc (BLU:LON) | 0.0 0 0.0% | Mkt Cap: 1.66m
- Published:
12 Oct 2015 -
Author:
Derren Nathan -
Pages:
7
Hilary Clinton has recently sent shockwaves through the Pharma & Biotech sector with her plan to lower prescription drug costs, bringing the issue of drug pricing squarely into public focus. Over September the S&P Pharma index was down some 20%, with the value of BELLUS Health shares suffering broadly in line, down 16% over the last month. This is at a time where the company’s rare disease pipeline is rapidly progressing. Its lead candidate KIACTATM is months away from releasing